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Abstract: Background: An interesting area of scientific research is the development of potential 
antiaging drugs. In order to pursue this goal, it is necessary to gather the specific knowledge about 
the adequate preclinical models that are available to evaluate the beneficial effects of new potential 
drugs. This review is focused on invertebrate and vertebrate preclinical models used to evaluate the 
efficacy of antiaging compounds, with the objective to extend life span and health span.  
Methods: Research and online content related to aging, antiaging drugs, experimental aging models 
is reviewed. Moreover, in this review, the main experimental preclinical models of organisms that 
have contributed to the research in the pharmacology of lifespan extension and the understanding of 
the aging process are discussed.   
Results: Dietary restriction (DR) constitutes a common experimental process to extend life span in 
all organisms. Besides, classical antiaging drugs such as resveratrol, rapamycin and metformin  
denominated as DR mimetics are also discussed. Likewise, the main therapeutic targets of these 
drugs include sirtuins, IGF-1, and mTOR, all of them being modulated by DR. 
Conclusion: Advances in molecular biology have uncovered the potential molecular pathways  
involved in the aging process. Due to their characteristics, invertebrate models are mainly used  
for drug screening. The National Institute on Aging (NIA) developed the Interventions Testing Pro-
gram (ITP). At the preclinical level, the ITP uses Heterogeneous mouse model (HET) which is 
probably the most suitable rodent model to study potential drugs against aging prevention. The 
accelerated-senescence mouse P8 is also a mammalian rodent model for aging research. However, 
when evaluating the effect of drugs on a preclinical level, the evaluation must be done in  
non-human primates since it is the mammalian specie closest to humans. Research is needed to 
investigate the impact of new potential drugs for the increase of human quality of life. 
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1. INTRODUCTION 
 Nowadays, life expectancy in the first-world countries 
has increased significantly due to the sanitary and alimentary 
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ago, the WHO reported that 125 million people were aged 80 
or older in the world [1]. Consequently, a growing need to 
develop drugs for the prevention of age-related diseases has 
emerged, constituting one major sanitary, social and eco-
nomic problem in the first-world countries. Among the many 
diseases associated with aging, we can emphasize the obe-
sity-related type 2 diabetes mellitus (T2DM) and hyperten-
sion, which represent major risk factors for other serious 
conditions such as stroke and cardiovascular disease. Also, 
neuropathies, metabolic syndrome, arthritis, or hypercholes-
terolemia worsen during aging, as well as pathological fac-
tors such as chronic inflammation and carcinogenesis [2-4]. 
 When trying to develop new antiaging drugs, it must be 
taken into account the inherent difficulties of assessing their 
effects in clinical trials, since these are very lengthy proc-
esses with a high number of variables [3]. It is noteworthy to 
mention that some of the drugs exhibiting antiaging effects 
are currently used in the cure of aging-associated diseases, 
e.g. metformin in diabetes’ treatment. However, we must 
differentiate between drugs aiming to reverse the aging proc-
ess and geroprotective drugs, which prevent premature aging 
and allow lifespan extending. In both cases, the development 
of drugs for the treatment of chronic disorders, such as dis-
turbances on cholesterol metabolism, rheumatoid arthritis, 
Parkinson’s disease (PD) and other neurodegenerative disor-
ders would be a good therapeutic strategy. These drugs 
would exert very significant antiaging effects through im-
provement in the quality of life. 
 When a researcher is interested in the study of aging 
process, he/she must keep several considerations in mind: 
1) It is important to understand the biochemical pathways 
related to the physiology of the aging process. Indeed, 
one of the main purposes of gerontology is the study of 
the biological process of aging. The physiology of aging 
involves complex mechanisms linked to a slow and pro-
gressive loss of cellular regulation, hormonal response, 
neurotransmitter activity, decrease of antioxidant en-
zymes and alterations on autophagy that lead to cellular 
and molecular damage [2, 3]. For instance, it is well 
known that lifespan increase depends on an efficient deg-
radation of cytoplasmic damaged organelles and aberrant 
proteins, which are eliminated through the autophagy-
lysosomal system [4]. Therefore, autophagy constitutes 
an important homeostatic mechanism that becomes al-
tered in the aging process and needs to be studied prop-
erly. Fortunately, aging-related pathways are highly con-
served in the evolution of the organisms whether they are 
worms, yeasts, flies or mammals, such as rodents and 
humans [5-10]. This provides a diverse array of experi-
mental models to be used. 
2) As it has been previously mentioned, aging research can 
also be conducted in many in vivo models, which have 
their own benefits and limitations. Hence, yeasts (Sac-
charomyces cerevisiae), nematodes (Caenorhabditis ele-
gans), fruit flies (Drosophila melanogaster), short-living 
fishes (Nothobranchius furzeri), rodents (mice and rats), 
dogs and non-human primates are widely used depending 
on the objective of the study [5]. For instance, if we aim 
to study whether a drug specifically extends lifespan, ex-
perimental models such as worms, flies, yeast or rodents 
are useful due to their short lifespan. By contrast, to as-
sess potential effects of drugs on diseases like T2DM or 
Alzheimer’s disease (AD), a closer approach to humans 
would be more appropriate, since this would allow longer 
and more elaborated treatments. Moreover, in many 
cases, it is also necessary to evaluate the potential side ef-
fects or toxicities of the drug of interest. For instance, if 
the aim is to search for tumorigenic effects or renal toxic-
ity, a mammalian rodent model is required. 
3) Finally, due to the lack of systemic complexity, in vitro 
studies have the disadvantage that they fail to show all 
mechanisms involved in the effect of the drug or its tox-
icity, as well as the influence of metabolism on its bio-
disponibility and elimination. As a consequence, they are 
not recommended for these studies. 
2. PHYSIOLOGICAL TARGETS ASSOCIATED WITH 
THE AGING PROCESS 
 The first step in longevity research is to identify which 
molecular pathways are relevant to human aging. In a second 
step, it is important to develop safe drugs that will delay ag-
ing or aging-associated diseases by targeting the molecules 
involved in those pathways [4-9]. In a recent manuscript 
published by López-Otín and colleagues, they discuss the 
most important factors involved in the aging process in dif-
ferent organisms [11]. 
2.1. Genetic and Epigenetic Changes 
 The physiological process of aging is a complex mecha-
nism. One of its main cellular hallmarks is the shortening of 
DNA’s ends (telomeres), which is initiated by the activity of 
specialized DNA polymerases known as telomerases [12-
15]. In addition to telomere shortening, other factors are in-
volved in the process of mammalian senescence, such as 
mitochondrial dysfunction, epigenetic alteration, genomic 
instability, altered intercellular communication and immune 
system activity alteration [11]. All these elements constitute 
potential targets for antiaging therapies [11]. Likewise, 
changes in DNA state, such as methylations and acetylations 
mediated by methyltransferases and histone acetylases, con-
stitute epigenetic alterations that are involved in the aging 
process not only in mammalians but also in invertebrates 
[11-15]. As a result, we can consider that an increase in ge-
netic alterations will be associated with the aging process. 
This statement can be of interest for those researchers aiming 
to detect genes involved in longevity. Also, heritable factors 
can affect positively or negatively the process of aging, thus 
influencing the resulting lifespan. For example, genetic 
background can favour age-associated diseases such as 
T2DM, hypertension associated with heart disease, neurode-
generative diseases and different types of cancer [16-21]. 
Some of the involved genes are the insulin-like growth factor 
1 (igf1), the antioxidant superoxide dismutase (sod), several 
cytokine genes (tnf-α, il-1α, etc.) and the serum par-
aoxonase/arylterase 1 (pon1), an enzyme involved in lipid β-
oxidation. Pon1 may have a prominent role in the develop-
ment of metabolic diseases such as atherosclerosis [16]. An-
other important gene involved in the longevity process is the 
Forkhead box O3 (foxo3a). Several studies on humans from 
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Japan, Germany, Italy and China demonstrated that in cen-
tenary subjects, foxo3a expression is linked to human lon-
gevity in both genders [17-21]. Overall, any drug that could 
modulate the expression or epigenetic modifications of these 
genes could be a promising strategy to improve age-related 
diseases and increase lifespan [21-24] (Table 1). 
2.2. Caloric Intake 
 In addition to genetic and epigenetic changes, the aging 
process could be regulated by caloric intake, as it has been 
strongly supported by current available evidence. Thus, re-
ducing caloric intake, also known as dietary restriction (DR) 
or caloric restriction (without causing malnutrition), results 
in the slowing of the aging process in an array of organisms, 
from yeast and flies to rodents and non-human primates [4, 
8, 11, 24]. Notwithstanding, DR does not escape from con-
troversy, since although it may be beneficial at the preclini-
cal level, in some human studies its effectiveness is more 
questionable [25, 26]. 
 Nonetheless, it might be possible that drugs that repro-
duce the effects of DR, also known as DR mimetics, could 
be a suitable strategy for anti-aging therapy [27]. The 
mechanism of how DR regulates longevity remains largely 
unknown, although several pathways that are highly con-
served from prokaryotes to eukaryotes have been proposed 
[27-29]. Some of these pathways are IGF signalling (whose 
downregulation extends lifespan), sirtuin 1 (SIRT1) activa-
tion, the mammalian target of rapamycin (mTOR) kinase and 
AMP-activated protein kinase (AMPK). Likewise, DR could 
modulate lifespan trough reduction of oxidative damage, 
activation of transcription factors and the control of endo-
plasmic reticulum stress response [2, 8, 11, 24]. 
 The silent information regulator 2 (Sir2) proteins, also 
known as SIRT1, are members of a highly conserved family 
of proteins that act as either nicotinamide adenine dinucleo-
tide (NAD+)-dependent protein deacetylases or mono-ADP-
ribosyltransferases [2-4, 7,11, 30]. Sirtuins are found in a 
variety of species, ranging from bacteria to humans. SIRT1 
is probably the best characterized sirtuin in the aging process 
[30-34]. It is well known that SIRT1 activation by DR or 
pharmacological intervention increases the acetylase activity 
of this enzyme, extending lifespan in yeasts, worms, flies 
and mammals [5]. Moreover, the SIRT1 activation and its 
regulation by resveratrol (RESV) is a well-known described 
mechanism of pharmacological intervention. It has been re-
ported that this natural compound can deacetylate and modu-
late the activation of SIRT1 and activate the PPARγ coacti-
vator 1α (PGC-1α) [31] (Fig. 1). In addition, PGC-1α exerts 
important physiological functions in the process of mito-
chondrial biogenesis, activation of antioxidant defenses and 
inhibition of amyloid-β (Aβ) peptides (the main component 
of amyloid plaques) production in Alzheimer’s disease (AD). 
 mTOR kinase is a multiprotein complex involved in the 
regulation of cellular metabolism [34]. Since mTOR activa-
tion accelerates the aging process in all organisms, its phar-
macological inhibition using rapamycin might constitute an 
interesting approach to increase lifespan [34, 35]. On another 
front, AMPK activation favours healthy aging and it is in-
volved in cell metabolism regulation. Indeed, metformin, an 
AMPK-activator drug which is used in T2DM treatment, 
could be another pharmacological approach to increase 
lifespan [13]. Moreover, AMPK could also activate SIRT1 
[28]. 
2.3. Mitochondrial Dysfunction 
 Mitochondria constitute master regulators of cellular en-
ergetics and are involved in free radical production [11, 35-
39]. According to the free radical theory of aging proposed 
by Denham Harman in 1956, aging favours continuous mito-
chondrial dysfunction, the consequence of which is an in-
crease in reactive oxygen species (ROS) production [37]. 
This process is cumulative and damages other biological 
structures, favouring further continuous mitochondrial dete-
rioration through positive feedback [11, 35]. 
 However, recent studies question the role of ROS in the 
aging process and the efficacy of antioxidants as anti-aging 
compounds [35-37]. To explain this discrepancy, the concept 
of “mitohormesis” has been introduced. This term tries to 
explain why the relationship between ROS generation and 
aging is not linear, and emphasizes that physiological con-
centrations of cellular ROS are necessary for life. Thus, 
eliminating ROS may be detrimental and could explain the 
fact that some antioxidants showed no improvements in 
lifespan. 
 Moreover, the participation of mitochondria in cellular 
physiological functions is complex [39]. Mitochondria are 
involved in the regulation of metabolic pathways, including 
cytosolic protein synthesis that may be altered in the aging 
process. They are also involved in the process of adequate 
proteostasis, maintaining chaperones that repair misfolded 
proteins and proteases that remove proteins damaged [40-
42]. Likewise, mitochondrial-associated membranes (MAMs) 
are important signalling sites, allowing continuous intercon-
nection with the endoplasmic reticulum (ER), having key 
roles in physiological processes such as apoptosis, autophagy, 
Ca2+ transport, inflammation and lipid synthesis [41, 42]. 
2.4. Protein Alteration and Endoplasmic Reticulum 
Stress 
 As it has been previously mentioned, some protein altera-
tions, such as protein misfolding, are also involved with the 
aging process. For example, accumulations of Aβ protein in 
AD and increased brain levels of α-synuclein in Parkinson’s 
disease have been reported [7]. This is usually regulated by 
the ubiquitin-proteasomal enzymes, autophagy and molecu-
lar chaperones, which prevent the accumulation of toxic lev-
els of unfolded or misfolded proteins [4]. Consequently, the 
accumulation of altered proteins is often caused by dysfunc-
tions in those processes that are supposed to prevent it, but 
have modified their activity due to aging. 
 Finally, the association between ER stress response and 
the longevity process remains poorly understood [40]. ER is 
involved in the synthesis and processing of secretory and 
membrane proteins. Its stress is characterized by the accumu-
lation of misfolded proteins in the ER lumen, and the activa-
tion of a stress signal pathway known as the unfolded protein 
response (UPR) [40-42]. The accumulation of unfolded or 
misfolded proteins occurs in aging-associated diseases such 
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as AD and PD [42]. Interestingly, lifespan in C. elegans is 
shortened by inhibition of stress sensors in the UPR signal-
ling pathways, such as inositol-requiring enzyme 1[36]. Ac-
cordingly, inhibition of ER stress by chemical drugs could 
improve the process of aging [36]. 
3. INVERTEBRATES AS PRECLINICAL EXPERI- 
MENTAL MODELS IN AGING RESEARCH 
 Although mammals are the ones most commonly used as 
experimental models for testing life-extending agents, the 
preclinical development of antiaging drugs usually starts in 
invertebrate organisms like nematodes, yeasts and flies [28]. 
One of the main advantages of these organisms is their short 
life expectancy, which allows a fast evaluation of the poten-
tial efficacy of the tested drugs. 
3.1. Caenorhabditis elegans as a Model of Aging 
 C. elegans is a suitable preclinical experimental model 
for the study of aging, mainly due to its short lifespan (around 
20 days) under normal growth conditions [43] (Table 2). This 
allows the performance of genetic dissection of the mecha-
nisms affecting aging and lifespan modification [44-47]. 
Moreover, several genes and signalling pathways associated 
with neurological disorders in humans have orthologues in 
C. elegans. For instance, genetic modifications increasing 
the levels of proteins like Aβ 42 (transgenic strain CL2006) 
or poly-glutamine (polyQ) in this worm, make C. elegans a 
useful model to study the molecular mechanisms involved  
in neurodegenerative processes such as AD, PD and 
Huntington’s disease (HD) [44-46]. Regarding to these brain 
diseases, interestingly, there is a high degree of evolutionary 
conservation of biochemical pathways between C. elegans 
and mammals [45-51]. 
 The insulin/IGF-1 signalling pathway is probably the 
most studied and frequently conserved mechanism that con-
trols aging and lifespan in this worm. Daf-2 gene is the ho-
molog of mammalian IGF-1 receptor genes for invertebrates. 
Thus, decreased Daf-2 signalling induces an increase in C. 
elegans lifespan and constitutes a suitable target for aging 
research. Another lifespan-involved gene is clk-1, which was 
characterized and found to be conserved among eukaryotes, 
including humans, rodents, and yeast (homologue of the 
Saccharomyces cerevisiae COQ7 gene) [51]. The clk-1 gene 
plays a prominent role in the biosynthesis of the mitochon-
drial electron transport component Coenzyme Q (CoQ, 
ubiquinone) [52]. Coenzyme Q is also involved in other 
processes such as fatty acid β-oxidation, uridine synthesis 
and antioxidant activities. In mammals, CoQ levels tend to 
decrease with aging, and this could explain, at least in part, 
 
Fig. (1). Signal transduction, nutrient sensing as well as epigenetic profile are nutrient dependent and converge on longevity regulation. 
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the differences found in aging processes among different 
organisms, as well as the susceptibility to aging or aging-
related diseases of some tissues such as the brain, which is 
especially sensible to oxidative stress. Accordingly, lower 
levels of CoQ levels have been found in cerebrospinal fluid 
of AD [53]. In this regard, Varela-López and colleagues re-
ported in an excellent revision that CoQ10 supplementation 
could be a suitable compound to prevent lifespan shortening 
due to its effect on mitochondrial function and antioxidant 
defences in mammals [54]. 
 Giving support to the free radical theory of aging, in-
creases in antioxidant enzymes such as SOD and catalase 
(CAT) have been found to increase worm lifespan [55, 56]. 
Notwithstanding, some reports have concluded that damage 
from ROS is unlikely to be a major primary determinant of 
aging in C. elegans [57, 59]. For instance, Van Raamsdonk 
and Hekimi showed that the knockout of sod-2, the main 
mitochondrial SOD in C. elegans, increases lifespan [60]. 
 This invertebrate model has been used to study numerous 
nutritional natural compounds (Fig. 1). Among them, RESV, 
a natural polyphenol compound found in red wine [28] 
stands out (Fig. 2). It has been found that a dietary supple-
mentation with RESV extends lifespan in C. elegans, hypo-
thetically through SIRT1 activation [28]. Interestingly, a 
screening with two natural compounds structurally similar to 
resveratrol such as quercetin and piceatannol, also demon-
strated SIRT1 activation. In addition, the antiaging effects of 
RESV observed in C. elegans (Fig. 1) might be attributed to 
its capacity for reducing oxidative stress through direct ROS-
scavenging activity and mitochondrial dysfunction minimi-
zation [28]. Furthermore, in a recent study, Shen and col-
leagues evidenced that piceatannol significantly extended C. 
elegans’ lifespan via the insulin/ IGF-1 signalling and sir-
2.1-dependent pathways. 
 Likewise, recent studies reported that the beneficial ef-
fects of RESV could be the result from the activation of 
SIRT3, liver kinase B1 (LKB1) and AMPK [30-32]. Indeed, 
RESV improves mitochondrial function and prevents against 
metabolic alterations by activating PGC-1α through SIRT1 
[30-32] Table 1. In addition, it was reported that C. elegans 
produces specific small molecules to control adult lifespan 
through the activation of SIRT1, giving support to the hy-
pothesis that sirtuins play an important role in regulating the 
cellular functions associated to lifespan [45, 47]. Taking all this 
data into account, it is clear that RESV exerts multiple bene-
ficial cellular effects through a complex mechanism of action. 
 Metformin is another drug with potential antiaging prop-
erties [13]. Preclinical data in C. elegans suggests that met-
formin mimics DR and increases lifespan and health span 
through the activation of AMPK [28, 35] (Table 1). Re-
cently, Cabreiro and colleagues suggested that the effects of 
metformin on C. elegans lifespan are indirect, through meta-
bolic modulation of intestinal microbiome (e.g. E. coli) pre-
sent in in vitro cultures of C. elegans [52]. The authors stated 
 
Fig. (2). Resveratrol increase lifespan in vertebrates and invertebrates preclinical models mainly through SIRT1 activation. 
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that Metformin alters the bacterial folate cycle, decreasing 
the S-adenosylmethionine levels in C. elegans, and thus 
slowing down its aging process by both AMPK activation 
and DR [52]. 
 In turn, Robida-Stubbs and colleagues reported that ra-
pamycin also increased lifespan in C. elegans, targeting 
mTOR and regulating SKN-1 (Protein skinhead-1) and 
DAF-16 (Abnormal DAuer Formation-16) [33]. Moreover, 
autophagy proved to be a key mechanism, since the effects 
of rapamycin were lost when the gene encoding the auto-
phagy modulator BEC-1 (the worm orthologue of mammal-
ian beclin 1) was suppressed [33]. 
 In addition to the three above-mentioned drugs, C. ele-
gans is a suitable preclinical model widely used to assess 
other potential molecules that mimic DR [28]. For example, 
molecules such as Celecoxib, aspirin, allantoin, trichostatin 
A, LY-294002 or geldanamycin, as well as natural products 
like flavonoids, have been evaluated in this model [44-50]. 
Therefore, the invertebrate C. elegans model has proved to 
be an effective approach for the evaluation of new drugs in 
the research field of aging. 
3.2. Drosophila Melanogaster as a Model of Aging 
 Drosophila melanogaster (DM) is a useful invertebrate 
model for the evaluation of antiaging drugs such as RESV, 
metformin, rapamycin, deprenyl, and lamotrigine, both in 
basic and in applied research [61-75] Table 2. Indeed, most 
of the research on lifespan and aging is focused in the DM 
model since the established vertebrate models are too long-
lived [54]. In addition, the high degree of functional conser-
vation in proteins between insects and humans makes DM 
more interesting for preclinical research (Table 2). 
 Proshkina and colleagues reviewed the main genes that 
have been identified as positive regulators of lifespan and 
longevity when they are overexpressed in DM [14]. Accord-
ing to their discussed data, the majority of longevity-
associated genes are involved in the control of metabolism, 
such as IGF-1R, phosphatidylinositide 3-kinase (PI3K), pro-
tein kinase B (PKB), AMPK and mTOR [4]. Therefore, the 
main pathways involved in the regulation of the process of 
lifespan and health span are also present in DM [64-66]. 
Note that the insulin receptor in DM is homologous to 
mammalian insulin and IGF-1 receptors. Furthermore, DM is 
useful for the study of many pathological mechanisms in-
volved in neurological disorders, especially AD, and since 
genetic manipulation in DM is feasible, transgenic flies can 
be generated in order to study some diseases such as AD and 
PD [66]. Indeed, the overexpression of mutant human Tau in 
DM nervous system allowed the detection of a pathologic 
increase in Tau phosphorylation [70]. On another front, Spindler 
and colleagues showed that the beta-adrenergic receptor has 
an important role in DM aging process [71]. The authors used 
two β-blockers, metoprolol and nebivolol, which allowed 
them to conclude that the β-receptor is fundamental in lifespan 
regulation [71]. Likewise, Jordens and colleagues reported 
that the effects of deprenyl on lifespan in DM are mediated 
through an increase in antioxidant enzyme activity [75]. 
 While the role of metformin on aging in DM is unclear, a 
recent study showed beneficial antiaging effects when this 
compound was administered in obese flies [65, 72]. Other 
drugs like pioglitazone showed antiaging properties targeting 
the insulin-signalling pathway, whereas RESV effects in DM 
could be explained through Sir2 activation of a NAD+-
dependent class III histone deacetylase [66]. Bearing in mind 
that Sir2 expression in DM modulates apoptotic and survival 
pathways through activation of Jun N-terminal kinase (JNK) 
and FOXO [73], the activation of SIRT1 may have a double 
effect in DM: antiaging and pro-apoptotic. Nevertheless, the 
role of RESV and sirtuins in fruit fly aging are still highly 
controversial in the field. Regarding rapamycin, it has been 
reported that this compound impairs motor performance and 
exerts pathophysiological effects in a DM model of Frie-
dreich’s ataxia [74]. However, rapamycin effects in DM 
lifespan are superior to those of DR restriction. Therefore, 
the antiaging pathways or genes activated by rapamycin 
seem to be different to those activated with DR in DM model 
[66]. 
3.3 Saccharomyces cerevisiae as a Model of Aging 
 The yeast Saccharomyces cerevisiae constitutes a com-
mon preclinical aging model used for biomedicine and aging 
research [76-79]. One of the advantages of using yeast cells 
as experimental models is that the basic metabolic pathways 
involved in neurodegenerative processes are well conserved 
Table 2. For instance, S. cerevisiae has been used as a pre-
clinical model to study human aging associated to neurode-
generative diseases including amyotrophic lateral sclerosis 
(ALS), PD, and HD [77]. Furthermore, S. cerevisiae allows 
easier quantification and analysis of longevity than other 
preclinical models [78] (Table 2). 
 Perhaps, one inconvenient of the S. cerevisiae model is 
the lack of the insulin-signalling pathway. However, precur-
sor pathways such as serine/threonine kinase AKT/ PKB and 
the cAMP-dependent protein kinase A (PKA) can be found 
in this model. Moreover, although DR has been reported to 
extend lifespan in a broad range of organisms such as yeasts, 
worms, fruit flies, mice, rats, and monkeys, Huberts and col-
leagues demonstrated that DR did not induce lifespan exten-
sion in S. cerevisiae [79]. For this reason, the authors suggest 
that studies on dietary restriction in yeast S. cerevisiae 
should be interpreted with caution. Nonetheless, the mTOR 
signalling pathway and SIR2 (mammalian SIRT1) are still 
the most studied longevity targets in the antiaging field in 
yeasts. 
4. VERTEBRATE PRECLINICAL EXPERIMENTAL 
MODELS ON AGING RESEARCH 
4.1. The Fish Nothobranchius furzeri as Model for Aging 
Research 
 The annual fish Nothobranchius furzeri, known as “tur-
quoise-killifish” and native of middle-east Africa, is a poten-
tial useful model for aging studies, mainly due to their short 
lifespan (2 to 6-8 months) [80-84] (Table 2). Some of the 
most interesting studies performed in this model were con-
ducted by Terzibasi and colleagues, reporting that DR causes 
an increase in fish longevity and health span, as well as an 
improved learning and delayed neurodegeneration [83]. 
Moreover, Kirschner and colleagues performed the first 
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analysis of genes involved in lifespan and health span in this 
fish [85]. On another front, D'Angelo and colleagues studied 
in depth the brain regulation of brain derived neurotrophic 
factor (BDNF) and published an important work of neuro-
anatomical structures between this model and mammals [86]. 
 Although few preclinical studies with drugs have been 
performed in this fish, Valenzano and colleagues were the 
first scientists who described the antiaging properties of 
RESV in N. furzeri [80-85]. They demonstrated that RESV 
supplementation in food extends vertebrate lifespan and im-
proves fish cognition [80]. Likewise, when Fluoro-Jade B 
staining (widely used to detect degenerating neurons) was 
performed in RESV-treated old fishes, labelling was absent. 
It was suggested that RESV exerted glial protective effects 
rather than a direct action over neurons [83]. Yet, few drugs 
apart from RESV have been evaluated in N. furzeri [87]. 
4.2. Rodents as Models for Aging Research 
 The National Institute on Aging (NIA) developed the 
Interventions Testing Program (ITP) for the scientific com-
munity working in aging research [88]. This program offers 
adequate protocols to reproduce studies, as well as interven-
tions to identify or evaluate potential compounds, diets and 
supplements that may have an impact on lifespan and pro-
mote healthy aging in rodent models [88-95]. 
 Three main laboratories are evaluating potential com-
pounds capable of preventing or delaying multiple aging 
diseases in mice: The Jackson Laboratory in Bar Harbor, 
Maine (TJL), the University of Michigan at Ann Arbor 
(UM), and the University of Texas Health Science Center at 
San Antonio (UT) [88-90]. In these preclinical studies, ge-
netically heterogeneous mice (HET) were obtained by cross-
ing progeny CB6F1 females with C3D2F1 males [88-92]. 
According to these laboratories, HET is probably the most 
suitable rodent model to study potential drugs against aging 
prevention [94] (Table 2). 
 Several compounds with previously reported antiaging 
properties have been evaluated in HET, including rapamycin, 
RESV, Green Tea Extract, curcumin and other additional 
drugs. Results with rapamycin were probably the most satis-
factory, as the drug proved effective even when the treatment 
started late in mice life [93]. Moreover, the antiaging effects 
were observed both in males and females. Although the ex-
act biochemical mechanisms involved in these effects remain 
to be elucidated, the inhibition of mTOR by rapamycin is 
involved in the regulation of antiaging effects in flies, 
worms, and yeast, leading to lifespan extension [2, 4, 8, 11, 
93]. Moreover, the deletion of ribosomal S6 protein kinase 
(S6K) 1 gene, a downstream target of mTOR, increases 
lifespan and improves aging effects in female mice [29]. 
Bearing in mind that the downregulation of mTOR by DR 
could also be involved in mice lifespan extension, the effects 
of rapamycin may be similar to those exerted by a DR diet 
on body metabolism. In fact, it was reported that rapamycin 
decreased weight gain and adiposity in rats [96]. Finally, the 
analgesic drugs aspirin and nordihydroguaiaretic acid also 
increased lifespan of HET males [90]. However, the molecu-
lar mechanism involved in this process was not mediated by 
DR [90]. Probably, the antioxidant and antiinflammatory 
properties of both drugs could account for the reported anti-
aging effects. 
 On the other hand, although RESV has shown promising 
effects in invertebrate models, no antiaging effects in HET 
has been achieved with this compound [92]. Thus, it remains 
to be ascertained whether SIRT1 activation by RESV could 
really explain the widely described antiaging properties of 
this drug on invertebrates and mammals. Moreover, although 
previous reported data suggests that statins may have an 
antiaging effect, simvastatin was also evaluated in HET with 
negative results [92]. Curcumin is another compound proven 
to be ineffective in HET despite previous studies demonstrat-
ing beneficial effects in murine models of AD and diabetes, 
as well as oxaloacetate, which increased lifespan in C. ele-
gans by a mechanism similar to DR [93]. 
 Another well-established murine model for aging-
associated disorders are the senescence prone inbred strains 
(SAMP), originally generated from AKR/J mice [96-103]. 
These mice, developed by Dr. Takeda, show features of ac-
celerated aging, including shortened life expectancy, mem-
ory loss and presence of Aβ depositions compared to the 
SAMR (senescence-resistant inbred strains) [31,32]. In addi-
tion to accelerated senescence, there are some SAMP strains 
which also manifest pathobiological phenotypes that are of-
ten used as characteristic features to differentiate the strains 
[96-99]. 
 Fujitsuka and colleagues reported that DR activates ghre-
lin signalling and improves health and lifespan in different 
murine models (SAMP8 and klotho-deficient mice) [97]. In 
turn, Porquet and colleagues also demonstrated the efficacy 
of RESV as lifespan and health span increaser in this mice 
strain, probably through the SIRT1 pathway activation [31]. 
Regarding the downregulation of insulin and/or IGF-1, the 
administration of tetrahydroxystilbene glucoside to SAMP8 
improved memory and prolonged lifespan by decreasing the 
activity of this pathway [3, 6, 98]. Moreover, the administra-
tion of (−)-epigallocatechin-3-gallate to SAMP8 mice im-
proved insulin resistance through the down-regulation of the 
mTORC1 pathway [99] (Fig. 3). mTOR is a kinase with a 
catalytic subunit of two functionally and structurally distinct 
complexes. Current evidence indicates that mTORC1 acts as 
a nutrient sensor that can be activated by insulin, and its in-
hibition by rapamycin increases longevity and postpones 
age-related diseases [3]. However, the inhibition of 
mTORC2 is likely deleterious to health, because it causes an 
impairment of glucose homeostasis and of the immune sys-
tem. Huperzine A is another compound evaluated in 
SAMP8, and it proved to be an antioxidant with beneficial 
effects in AD treatment [104]. All these studies support the 
usefulness of SAMP8 as a model for drug development 
against aging-associated metabolic diseases [99-104]. 
 Another interesting murine model of aging is the klotho 
mutant mice, characterized by a deletion in the klotho gene. 
Klotho mutant mice show common features with human ag-
ing process, such as short lifespan, hypokinesia, infertility, 
arteriosclerosis, osteoporosis and brain alterations related to 
neurological disorders [105-107]. Indeed, the klotho 
(KLOTHO) protein appears to have antiaging properties, and 
several researchers supported the hypothesis that klotho 
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functions as a human aging-suppression molecule [107]. 
This notion is supported by the fact that the overexpression 
of the klotho gene extends lifespan in mice [105-107]. Al-
though few pharmacological studies have been performed in 
this model, Kuro and colleagues reported an increase in brain 
oxidative stress and memory loss in klotho mutant mice that 
was improved by the administration of the antioxidant α-
tocopherol [107]. Furthermore, it has been suggested that 
drugs which increase the brain levels of KLOTHO protein 
could be a promising strategy for treating AD [105]. 
 The Snell and Ames dwarf mice are also interesting 
models of delayed aging and increased longevity since they 
show an average increase in life expectancy of the 40% 
[108]. Snell dwarf mice live longer than their normal sib-
lings, showing significant increases in both average and 
maximal lifespan [108-111]. Both mice are characterized by 
the lack of growth hormone (GH) producing cells in the pi-
tuitary gland [109]. Thus, mutations in the Snell dwarf gene 
Pit1 (pituitary transcription factor 1) reduced GH, prolactin, 
and thyroid stimulating hormone (TSH) production. The 
Ames dwarf gene Prop1 (Prophet of Pit1) encodes for tran-
scription factors that control pituitary development, thus 
causing alterations in the hormonal system, decreasing the 
levels of GH, prolactin and TSH [108-111]. In turn, GH is 
involved in the regulation of IGF-1 secretion in the majority 
of tissues. Therefore, increasing life expectancy could be 
related with a decrease in GH, which, in turn, would de-
crease the IGF-1 signalling pathway [109-111]. These mice 
models of aging confirm the importance of the IGF-1 de-
crease in lifespan extension, and point to the deficient regu-
lation of GH through Prop-1 and Pit-1 mutations as one of 
the most important effects on longevity [109, 110]. Moreo-
ver, it has been recently shown that TSH treatment partially 
restores life extension of the Snell mice, suggesting that thy-
roid hormone and GH/IGF-1 play a role in lifespan extension 
[108]. The IGF-1 knockout mice are not viable (they die in 
the first week after birth), it may be possible that a partial or 
a moderate loss of the Igf1r gene decreases insulin and IGF-
1 signalling, thus extending lifespan in mice [112]. 
 Mice with fat-specific disruption of the insulin receptor 
gene (FIRKO), constitute another suitable preclinical model. 
These mice show reduced insulin receptor expression in adi-
pose tissue and a lower expression of genes involved in oxi-
dative stress, which could explain their higher lifespan [112, 
113]. An additional rodent model to study the aging process 
and age-related diseases are the OXYS rats [114]. This rat 
strain is characterized by an overproduction of oxygen radi-
cals.	   Furthermore, OXYS rats show an age-related mito-
chondrial dysfunction, being the most probable cause of their 
enhanced oxidative stress and accelerated senescence [114].	  
 
Fig. (3). Effect of some drug treatments in mice models of aging. 
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It has been reported that OXYS rats treated with rapamycin 
0.1 or 0.5 mg/kg of body weight per day from the age of 1.5 
to 3.5 months show an improvement in some aging-related 
parameters, such as locomotion and exploratory activity, in 
addition to inhibit tau phosphorylation, which is a sign of 
brain damage [114]. Notwithstanding, rapamycin and related 
analogous compounds (i.e., everolimus) have a potential risk 
of presenting adverse side effects, including metabolic al-
terations (hypertriglyceridemia), pain, haematological cell 
alterations, diarrhoea and others. Moreover, it is well known 
their ability to induce immunosuppression, thus increasing 
the risk of infections [115]. 
Table 1. Relevant antiaging pathways modulated by the main drugs that mimics dietary restriction. 
Antiaging Strategy  Pathway (s) Modulated  Antiaging Effects 
Dietary restriction  AMPK, SIRT-1, mTOR, PI3k/Akt pathway,  
IGF-1, FOXO, PGC-1α 
Decreases stress response, improves mitochondrial biogenesis, 
improves cellular maintenance, reduces inflammation. 
Metformin  AMPK (Activation), SIRT1 activator 
via its effect on AMPK, PGC-1α 
Decreases stress response, improves mitochondrial biogenesis, 
improves cellular and genome maintenance, reduces inflammation. 
Resveratrol SIRT-1 (Activation), NF-κB inhibition, p53, 
FOXO, PGC-1α 
Decreases stress response, improves mitochondrial biogenesis, 
improves cellular and genome maintenance, reduces inflammation. 
RAPAMYCIN mTOR (inhibition), inhibition of the eukaryotic 
translation initiation factor 4E (eIF4E)-binding 
proteins (4E-BPs).  
Increases autophagy, improves mitochondrial biogenesis. 
Selegiline/Deprenyl SOD and CAT Antioxidant effects. 
Aspirin and Nordihy-
droguaiaretic acid 
Antioxidant (SOD, CAT) and anti-inflammatory 
(COX-1 and NF-κB inhibition) 
Decreases stress response, reduces inflammation. 
 
Table 2. Summary of preclinical model’s strengths and limitations in antiaging research. 
Models of Aging  Strengths Limitations	  
Caenorhabditis elegans Short life expectancy, fast evaluation of the potential efficacy of 
the tested drugs. Lower research costs. Simple neuronal system 
Invertebrate model. Toxicity studies. Studies on me-
tabolism of drugs.	  
Drosophila melanogaster Short life expectancy, fast evaluation of the potential efficacy of 
the tested drugs. Lower research costs. 
Invertebrate model. Toxicity studies. Studies on me-
tabolism of drugs.	  
Saccharomyces cerevisiae Short life expectancy, fast evaluation of the potential efficacy of 
the tested drugs. Lower research costs. 
Invertebrate model. Toxicity studies. Studies on me-
tabolism of drugs.	  
Nothobranchius furzeri Appropriate for anti-aging drug research testing Organs are quite different to those in humans. Studies 
on aging-associated diseases, such as T2DM and AD.	  
Senescence prone inbred 
strains 
Appropriate for anti-aging drug research testing and neurodegen-
erative diseases, such as AD. 
Significant differences at a pharmacokinetical drug 
level. Lifespan extension could also vary between ro-
dent’s genders.	  
HET mice Developed by the National Institute on Aging interventions 
testing program as the most adequate mammal mice model in 
drug research. 
Differences at a pharmacokinetical drug level. Lifespan 
extension could also vary between rodent’s genders. 
klotho mutant mice Common features with human aging process, such as short 
lifespan, hypokinesia, infertility, arteriosclerosis, osteoporosis 
and brain alterations related to neurological disorders. 
Differences at a pharmacokinetical drug level.	  
Rodent models of progeria Effects of premature aging. Reduction in time, labor and costs 
for lifespan studies, as well as the ability to target accelerated 
aging to specific organs. 
Differences at a pharmacokinetical drug level. 
Dogs Useful in studies with drugs related with AD. Cognitive evaluation and behavioral studies.	  
Nonhuman primate mod-
els of aging 
Evaluate behavioral or cognitive decline tests. Allow the investi-
gation of molecular mechanisms of neurodegenerative diseases. 
Best extrapolation of the results to our specie. 
Expensive. Isolation in cages is difficult.	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 Some studies aiming to evaluate antiaging drugs have 
been performed in wild-type mice. For instance, Arriola-
Apelo and colleagues reported that an intermittent rapamycin 
treatment in female C57BL/6 mice extends lifespan. In addi-
tion, it decreases the risk and the occurrence of undesirable 
side effects caused by the drug [116]. Moreover, this study 
demonstrated that a close monitoring of the dose of adminis-
tered rapamycin at preclinical level could be a potential 
treatment of diseases related with the aging process. 
 Finally, selegiline (deprenyl) is another drug that has 
been reported to have an antiaging effect. It was originally 
developed as an antidepressant, and later proved to be a 
MAO B inhibitor for PD treatment [117-121] Table 1. The 
first preclinical evidences of its antiaging effects were re-
ported by Knoll and colleagues, who showed that repeated 
administration of deprenyl prolonged lifespan of male rats 
[118] (Table 2). Further studies carried out by Kitani and col-
leagues in Fischer 344/Du (F344/Du) rats confirmed the 
lifespan-increasing properties of this drug [117]. The upregu-
lation of antioxidant SOD and CAT activities in the majority 
of animal tissues may be the mechanism involved in this 
antiaging effect [119-121]. In addition, it has been hypothe-
sized that the beneficial effects of deprenyl are more com-
plex, and could be mediated by homeostatic mechanisms 
which regulate the aging process through a neuro-immuno-
endocrine axis [122]. 
4.3. Rodent Models of Progeria 
 Premature aging-like syndromes in humans constitute an 
unusual group of rare genetic diseases [123-126], in which 
the effects of premature aging could affect several organs 
and tissues as well as exhibit some symptoms seen in the 
physiological aging [127]. These syndromes include clini-
cally and genetically heterogeneous diseases such as ataxia-
telangiectasia, Bloom syndrome, Cockayne syndrome, Fan-
coni anaemia, Hutchinson-Gilford syndrome, Rothmund-
Thomson syndrome, trichothiodystrophy, xeroderma pig-
mentosum, and Werner syndrome (also known as adult 
progeria) [124-135]. The scientific community has been de-
voted on developing animal models capable of reproducing 
all symptomology of these diseases in order to understand 
their pathogenesis and, design and develop therapeutic drugs 
capable of halting them [132]. In general, the advantages of 
working with progeria rodents include the reduction in time, 
labor and costs for lifespan studies, as well as the ability to 
target accelerated aging on specific organs (Table 2). Moreover, 
premature aging mice mutants may display more pronounced 
aging features than normal mice (e.g. neurodegeneration in 
AD, which is not a very pronounced aging feature in wild 
type mice), and they are useful to investigate underlying 
mechanisms. One of these models are the Ercc1 mutant 
mice, which show a deficiency in the DNA excision-repair 
gene Ercc due to a deletion mutation in one allele [124]. This 
causes a slight retardation in embryonic and early post-natal 
development, as well as a reduced lifespan of only 4–6 
months [124]. These Ercc1 mutant mice suffer skin, liver 
and kidney malfunctions, neurodegeneration, arrested devel-
opment, osteoporosis, bone marrow pathologies, progressive 
ataxia, loss of vision and hearing and early death [134]. Re-
cently, Vermeij and colleagues reported that dietary restric-
tion in Ercc1 mutant mice increased resistance to DNA dam-
age-induced stress and improved antioxidant defences, al-
tered insulin and other hormonal signalling pathways and 
extended lifespan by 180% [126]. Likewise, DR in Xpg−/− 
mouse mutant, another nucleotide excision repair-deficient 
progeroid mutant mice, induced an increase of median 
lifespan of approximately 80% [126, 135]. Therefore, DR 
could be a suitable antiaging intervention to treat progeroid 
syndromes associated with defective DNA-repair [126]. 
 Another model of progeria is the Lmna−/− mice, which 
carry an autosomal recessive mutation in the Lmna gene 
[127]. Lmna gene encodes the protein LMNA, also known as 
Lamin A/C, which belongs to the lamin family of proteins. 
These cytoskeletal proteins form a complex meshwork in the 
internal nuclear envelope [128]. Mutations in laminin genes 
LMNA, LMNB1 and LMNB2 are responsible for several dis-
eases that are known as laminopathies, which include prema-
ture aging syndromes. Thus, Lmna−/− mice develop a phe-
notype resembling Hutchinson-Gilford Progeria, with marked 
growth retardation, skin and bone dysfunctions and prema-
ture death approximately by 4-6 weeks of age [127-129]. 
 Ramos and colleagues showed that Lmna–/– mice fed with 
a diet supplemented with rapamycin lived significantly 
longer than animals which were fed with an identical diet 
without rapamycin (56% increase in mean lifespan) [128]. 
Moreover, rapamycin improved cardiac and muscle function, 
probably through autophagy-enhancing mechanisms, since 
rapamycin inhibits mTORC1 hyperactivation in Lmna−/− 
mice [128]. This remarks the importance of understanding 
the links between mTORC1 signalling and autophagy in 
progeria-like diseases, as well as in physiological aging. In 
turn, Liu and colleagues reported that RESV treatment in 
Zmpste24-/- mice (a model with prelamin A accumulation and 
a phenotype of premature aging) resulted in rescued adult 
stem cell decline and improved body weight loss, trabecular 
bone structure and bone mineral density [127]. Mice treated 
with RESV also showed increased lifespan as compared to 
untreated mice. Thus, this study suggests a therapeutic strat-
egy based on SIRT1 pathway activation by RESV for 
Hutchinson-Gilford Progeria. In contrast, Strandgren and 
colleagues demonstrated that RESV treatment did not im-
prove skeletal abnormalities in a mouse model with the os-
teoblast and osteocyte-specific inducible transgenic expres-
sion of the most common Hutchinson-Gilford Progeria muta-
tion [133]. It is noteworthy that the phenotypes in LmnaHG/+ 
mice closely resemble those in Zmpste24–/– mice [133]. Fi-
nally, Fong and colleagues demonstrated that the farnesyl-
transferase inhibitor ABT-100 delays the onset of many 
progeroid symptoms and significantly improves lifespan in 
Zmpste24−/− mice [129]. Likewise, Yang and colleagues 
reported that farnesyltransferase inhibitors controlled body 
weight, prevented loss of adipose tissue, improved bone 
mineralization, and ameliorated disease phenotypes in 
LmnaHG/+mice [130]. 
4.4. Dogs as a Model of Aging 
 Although dogs are not often used in geroscience, they are 
suitable models due to their brain similarities with humans, 
showing similar age-related cognitive decline, presence of 
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oxidative damage and Aβ deposits [136-138]. For this rea-
son, dogs are often used to study drugs with potential effi-
cacy on cognition and in AD research (Table 2). In addition, 
the use of dogs has some advantages: they are easy to handle 
and they allow predictive validity in extrapolating the results 
to clinical trials in humans, due to high similarities in phar-
macokinetics and metabolism of drugs [136,137]. Beagles 
are probably the most widely used dogs in preclinical re-
search, having an average life expectancy of 14 years. 
 Although there are some studies assessing the effects of 
DR in dogs [136], studies evaluating the antioxidant effects 
of some drugs are probably the most detailed. Thus, some 
research groups have evaluated the effect of antioxidant 
compounds such as lipoic acid and performed treatments 
with antioxidant diets, including a broad spectrum of anti-
oxidants and mitochondrial co-factors [136]. In general, the 
results were contradictory: whereas some studies reported 
cognitive improvements, others described no cognitive bene-
fits in aged beagles [138, 139]. 
 Finally, it is worth to mention that the Dog Aging Pro-
ject, directed by Promislow and Kaeberlein from the Univer-
sity of Washington [140]. This project aims to enhance the 
longevity and health span in people’s pets, since this could 
improve people’s quality of life. To reach this goal, the Dog 
Aging Project has two major aims: they are performing a 
longitudinal study of aging in dogs and an intervention trial 
with rapamycin to prevent disease and extend healthy lon-
gevity in middle-aged dogs. 
4.5. Nonhuman Primate Models of Aging 
 Choosing primates as an experimental model has several 
disadvantages. For instance, it is an expensive animal model 
which carries health risks and whose isolation in cages is 
difficult (Table 2). Besides, choosing a nonhuman primate 
(NHP) model with short life expectancy is mandatory in or-
der to not extend excessively the studies with drugs [141-
149]. Obviously, the main advantage of NHP is that they are 
the closest model to humans, and therefore the results will be 
better reproduced in our species [142]. 
 The Rhesus macaque (Macaca mulatta), is an example of 
NHP used in aging research, but its relatively long lifespan 
(around 40 years) is an important inconvenience in studies 
with drugs due to the high costs associated [142]. Nonethe-
less, Jimenez-Gomez and colleagues reported that chronic 
RESV administration (2-year) in M. mulatta under an obe-
sity-inducing diet associated with insulin resistance im-
proved the metabolic body status [150]. Authors concluded 
that the administration of RESV was safe in this NHP and 
the effects of the drug would probably be mediated through 
the inhibition of JNK activity, which inhibits serine phos-
phorylation of IRS-1. SIRT1 activation could also contribute 
to beneficial effects of RESV. In turn, Colman and col-
leagues reported positive effects of CR in this model of NHP 
[145]. 
 The common marmoset (Callithrix jacchus) is a widely 
used NHP model in biomedical aging research, due to its 
short lifespan and its small size [142]. Marmosets also ex-
hibit some age-related characteristic diseases similar to those 
observed in humans, like neurological diseases, cancer and 
diabetes. Furthermore, when compared with other NHP, C. 
jacchus is much more docile and does not transmit diseases 
to humans, thus offering practical advantages. Ross and col-
leagues reported that long-term rapamycin-treated marmo-
sets had a reduced mTOR signalling, finding no negative 
side effects at previously used doses [146]. Likewise, Lele-
gren and colleagues reported that a long-term rapamycin 
treatment (14 months) in the common marmoset induced the 
activation of some of the molecular components responsible 
for the regulation of proteostasis associated with a significant 
reduction of mTOR [141]. Marmosets are also useful as pre-
clinical models in the development of drugs for the treatment 
of PD [144]. Thus, Bourdenx and colleagues developed and 
administered a recombinant viral vector overexpressing mu-
tated α-synuclein, a major constituent of Lewy bodies, in 
order to evaluate the effects of aging on the development of 
PD [144]. Likewise, numerous studies have been conducted 
in this NHP model to evaluate the effect of the neurotoxin 
MPTP, as a preclinical model for PD [145]. Furthermore, 
Palazzi and colleagues reported the appearance of Aβ depos-
its in the brains of marmosets, so this NHP could be a useful 
model to evaluate potential dugs for the treatment of spo-
radic AD related to aging [149]. One of the advantages of 
this experimental NHP model is that it allows evaluating the 
efficacy of drugs affecting cognitive processes which may 
decrease with aging, with an easier extrapolation to humans 
than invertebrate models. 
 DR studies have also been performed in another NHP 
model, specifically the grey mouse lemur (Microcebus mur-
inus), which originates from Madagascar and has a life ex-
pectancy of about 10 years. This NHP is used in the 
“RESTRIKAL” study, which investigates the long-term ef-
fects of DR and/or supplementation of a mimetic compound 
of RESV on the aging process and lifespan [151]. Marchal 
and colleagues demonstrated in this NHP that 1 year of 
treatment with both strategies was safe; however, RESV 
produced an activation of energy metabolism, while DR de-
creased energy expenditure [151-154]. 
CONCLUSION 
 This review discusses the most common and appropriate 
preclinical models used in aging research, and the main bio-
chemical mechanisms involved in the aging process. 
 The major biochemical pathways associated with aging 
are the activation of sirtuins (specifically SIRT1), and the 
inhibition of IGF-1 and mTOR pathways. Therefore, the 
development of drugs that increase lifespan and health  
span depends on the elucidation of these pathways which, 
are highly conserved in all species from prokaryotes to  
eukaryotes. 
 Most compounds assessed in aging research are based in 
drugs that mimic and induce the health effects of DR. Con-
sequently, most preclinical research in experimental models 
of aging is based on RESV studies, rapamycin and, to a 
lesser extent, metformin. The development of DR mimetic 
drugs is difficult, since it is also necessary to evaluate the 
toxic effects of a specific chronic treatment on different or-
gans and tissues. Thus, studies in invertebrates such as C. 
elegans, Drosophila and S. cerevisae are useful for the per-
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formance of initial screening of new compounds and confir-
mation on their potential applications in aging. The main 
advantage on the use of invertebrate models is the rapid gen-
eration of sufficient amount of data in a short period of time 
and the lower research costs when compared to studies in 
mammals. Furthermore, several studies suggest that DR in-
duced lifespan extension in invertebrates is mediated by the 
down-regulation of nutrient signalling pathways. This ex-
tends longevity by activating stress-resistance transcription 
factors that regulate the expression of genes involved in pro-
tection against oxidative stress, DNA repair, and metabo-
lism. Both yeast and C. elegans are powerful invertebrate 
models for aging research studies, as it is demonstrated by 
the fact that most processes that modulate aging (e.g., insulin 
signalling and mitochondrial alteration, sirtuins, TOR, ca-
loric restriction) have been originally and extensively inves-
tigated in these models. In addition, C. elegans has some 
important advantages as compared to other invertebrate 
models, such as their simple neuronal system and the fact 
that some genes are homologous to those of human. Moreo-
ver, mutant lines with aging phenotypes have been devel-
oped in order to investigate the role of specific proteins in 
specific particular aging processes. In spite of this, the ex-
trapolation of results obtained in invertebrates to humans is 
not possible without assessing further animal models. Con-
sequently, mammalian models are essential in the develop-
ment of molecules with antiaging effects, as well as to im-
prove aging-associated conditions such as T2DM, coronary 
and neurodegenerative diseases. 
 Although significant progresses in N. furzeri have been 
achieved in geroscience, this preclinical model still presents 
many limitations. Firstly, the model is not a good choice 
when studying aging-associated diseases such as T2DM and 
AD. Moreover, there are limitations to the studies of organs, 
which logically are quite different to those in humans. How-
ever, the short lifespan of N. furzeri is one of the main ad-
vantages that this model can offer in the discovery of genes, 
proteins or pathways associated to vertebrate aging. Like-
wise, N. furzeri could also be appropriate for antiaging drug 
research testing. 
 Although rodents are genetically much closer to humans 
than invertebrates, they still present significant differences at 
a pharmacokinetic drug level. Moreover, we have to be cau-
tious about age and DR in this model. Theoretically, DR can 
increase lifespan, although this effect is not uniform depend-
ing of mouse strain. For instance, male C57BL/6J mice re-
spond to DR with an increase in median and maximum 
lifespan, while other mice strains do not. In addition, some 
age related diseases appear at 24 months of age in C57BL/6J 
mice, which is equivalent to 70 years old in humans. There-
fore, lifespan and health span studies in rodents should be 
performed on this time period. Moreover, an important focus 
for future research is the fact that the degree of lifespan ex-
tension could also vary between the gender of rodents. Most 
authors point to HET mice developed by the National Insti-
tute on Aging interventions testing program as the most ade-
quate mammal mice model in drug research [88-95]. The 
studies performed in HET mice allowed the evaluation of 
compounds hypothesized to delay aging and also prevent 
diseases associated with the aging process in other preclini-
cal models. Hence, the ITP program has assessed the efficacy 
of various antiaging compounds such as anti-inflammatory 
drugs, Green Tea Extract, Curcumin, RESV, rapamicyn, etc. 
Notwithstanding, the SAMP8 mice is also useful as model of 
aging, since it allows the reproduction of chronic diseases 
closely related to humans. This model also allows the re-
trieval of different tissues such as heart, liver and brain for 
further analysis. Moreover, it shows cognitive loss and de-
velops a symptomatology similar to AD. Likewise, it can be 
used to study the emergence of T2DM in mice under a high 
fat diet or to reproduce some neurological diseases after the 
administration of neurotoxins, such as PD or epilepsy. 
 Regarding dogs as experimental models in aging, they 
are especially useful in studies with drugs related with AD; 
however, some important limitations exist, mostly associated 
with cognitive evaluation and behavioural studies. 
 Prior to any clinical trial, the validation of an antiaging 
drug in NHP will probably be essential. In addition, NHP are 
important models to evaluate behavioural alterations or cog-
nitive decline that cannot be investigated in other animal 
models. Therefore, they represent an extremely valuable tool 
to improve our knowledge in aging diseases and to establish 
new potential therapeutic strategies for aging and aging-
related diseases like AD. Indeed, although they have their 
intrinsic limitations, NHP models could allow the investiga-
tion of molecular mechanisms underlying AD, as well as its 
histopathological modifications using the closest models to 
human physiology [149, 153]. Currently, shorter-lived pri-
mate models as the common marmoset are available for pre-
clinical studies. Likewise, recent studies of aging research 
with NHP have demonstrated the safety and efficacy of DR 
and some antiaging drugs such as RSV and rapamycin [141, 
146, 150, 151]. Notwithstanding, it is important to keep in 
mind that all animal models reproduce only some aspects of 
the aging process and it is not possible to recapitulate the 
entire human clinical picture [142]. 
 Finally, taking into account all the preclinical results pub-
lished so far, we emphasize that rapamycin is the most prom-
ising drug in the field of geroscience. In addition to its anti-
aging effect, it has shown neuroprotective effects in experi-
mental models of AD and PD. We also believe that mTOR 
could be a promising target for drug development in antiag-
ing research, neurodegenerative diseases and Hutchinson–
Gilford progeria syndrome. In spite of this, we must not for-
get the potential side effects of rapamycin in a chronic treat-
ment. The use of safer drugs, or a combinatory drug treat-
ment such as rapamicyn with metformin and resveratrol, 
may be advantageous in chronic treatments aiming to extend 
human health and lifespan or preventing aging-related  
diseases. 
LIST OF ABBREVIATIONS 
AD = Alzheimer’s disease 
ALS = Amyotrophic Lateral Sclerosis 
AMPK = AMP-activated protein kinase 
Aβ = Amyloid-β protein 
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CAT = Catalase 
CoQ = Coenzime Q 
DM = Drosophila melanogaster 
DR = Dietary Restriction 
ER = Endoplasmic Reticulum 
GH = Growth Hormone 
HD = Huntington disease 
HET = Heterogeneous Mice Model 
IGF-1 = Insulin Growth Factor 1 
IL-1β = Interleukin-1beta 
IL-6 = Interleukin-6 
ITP = Interventions Testing Program level 
JNK = Jun N-terminal Kinase 
LKB1 = Liver Kinase B1 
mTOR = Mammalian Target of Rapamycin 
NAD = Nicotinamide adenine nucleotide 
NHP = Non Human Primate 
NIA = National Institute on Aging 
PD = Parkinson’s disease 
PKB = Protein Kinase B 
Pon1 = paraoxonase1 
RESV = Resveratrol 
ROS = Reactive oxygen species 
SIRT1 = Sirtuin 1 
SOD = Superoxide dismutase 
T2DM = Type 2 Diabetes Mellitus 
TNFα = Tumor necrosis factors alpha 
TSH = Thyroid Stimulating Hormone 
UPR = Unfolded Protein Response 
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